C-type lectin receptor Dectin3 deficiency balances the accumulation and function of FoxO1-mediated LOX-1+ M-MDSCs in relieving lupus-like symptoms

Dan Li1, Li Lu1, Wei Kong2, Xiaoyu Xia1, Yuchen Pan1, Jingman Li3, Jiali Wang1, Tingting Wang1, Jun Liang2, Huan Dou1,3,5 and Yayi Hou1,3,5

© The Author(s) 2021, corrected publication 2023

Recent studies indicate that Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) can function as the signal of pattern recognition receptors, which play a pivotal role in the pathogenesis of the autoimmune disease. Systemic lupus erythematosus (SLE) is a classic autoimmune disease. Previous reports mainly focused on the potential role of TLRs in regulating the development of SLE, but little is known about the role of CLRs in the progression of SLE. Our previous studies showed that the inflammation-mediated accumulation of myeloid-derived suppressor cells (MDSCs) including granulocytic (G-MDSCs) and monocytic (M-MDSCs) participated in the pathogenesis of lupus. Mice deficient in Card9 (the downstream molecule of CLRs) were more susceptible to colitis-associated cancer via promoting the expansion of MDSCs. Whether the abnormal activation of CLRs regulates the expansion of MDSCs to participate in the pathogenesis of lupus remains unknown. In the present study, the expressions of CLRs were examined in both SLE patients and mouse models, revealing the expression of Dectin3 was positively correlated with SLEDAI. Dectin3 deficiency retarded the lupus-like disease by regulating the expansion and function of MDSCs. The mechanistic analysis revealed that Dectin3 deficiency promoted FoxO1-mediated apoptosis of MDSCs. Syk-Akt1-mediated nuclear transfer of FoxO1 increased in Dectin3-deficient MDSCs. Notedly, the accumulation of M-MDSCs mainly decreased in Dectin3+/− mice, and the nuclear transfer of FoxO1 negatively correlated with the expression of LOX-1 on M-MDSCs. The silencing of FoxO1 expression in Dectin3−/− mice promoted the expansion of LOX-1+ M-MDSCs in vivo, and LOX-1+ M-MDSCs increased the differentiation of Th17 cells. Both LOX-1 expression on M-MDSCs and Dectin3 expression on MDSCs increased in patients with SLE. These data indicated that increased LOX-1+ M-MDSCs were related to the exacerbation of SLE development and might be potential target cells for the treatment of SLE.

Cell Death and Disease (2021) 12:829; https://doi.org/10.1038/s41419-021-04052-5

INTRODUCTION

Previous studies indicated that pattern recognition receptors might participate in the pathogenesis of chronic inflammatory conditions and autoimmune diseases [1]. Toll-like receptors (TLRs) and some members of C-type lectin receptors (CLRs) superfamily play a pivotal role in the autoimmune disease [2–5]. Systemic lupus erythematosus (SLE) is a complex, multi-system autoimmune disease caused by a combination of genetic and environmental factors [6]. Previous reports mainly focused on the potential role of TLRs in regulating the development of SLE [7]; however, recent studies indicated that CLRs played a vital role in the progression of SLE. One study suggested that the defective expression and function of Dectin1 on monocytes contributed to the progression of SLE [2, 4, 5]. Meanwhile, another study indicated that the expression of Dectin1 on dendritic cells from SLE patients increased, enhancing the production of IL-1β and promotes Th17 differentiation [5]. However, the role of CLRs in modulating the innate immune response to participate in the development of SLE remains ambiguous.

Myeloid-derived suppressor cells (MDSCs) are immature heterogeneous myeloid-derived cells characterized by immature state and significant ability to suppress the T-cell response. MDSCs significantly expand during inflammation, tumor, and infection, which are comprised of polymorphonuclear (G-MDSCs) and monocytic (M-MDSCs) [8–10]. G-MDSCs are phenotypically and morphologically similar to neutrophils, and M-MDSCs are more similar to monocytes [9]. Recently, MDSCs were suspected to play a vital role in the pathogenesis of SLE. MDSCs were reported to be increased in peripheral blood of SLE patients and promoted Th17 polarization by secreting Arg-1 in vitro [11]. We previously found that MDSCs promoted IL-1β-mediated Th17 polarization and inhibited Treg differentiation by reactive oxygen species (ROS) production in MRL/lpr mice [12]. Meanwhile, we found that MDSCs induced podocyte injury by increasing ROS in lupus nephritis and...
A mammalian target of rapamycin (mTOR) inhibitor INK128 relieved the symptoms of pristane-induced lupus via downregulating the expansion of MDSCs [13, 14]. The depletion of MDSCs in humanized NOD/SCID mice significantly alleviated the symptoms of SLE [11]. However, the molecular mechanism to regulate the accumulation and function of MDSCs in SLE remains unclear.

The adaptor protein Card9, the downstream signal molecules of CLRs, was reported to attenuate the progression of colitis-associated colon cancer by restricting the expansion of MDSCs [15]. CARD9 also protected against lung cancer development by reducing the expansion of MDSCs and indoleamine 2,3-dioxygenase (IDO) production [16]. The accumulation of fungus-mediated MDSCs was dependent on the activation of Dectin1 [17]. β-Glucan induced the differentiation and function of M-MDSCs via the Dectin1 pathway to enhance antitumor immune response [18]. Recently, some studies implicated some CLRs as risk genes for the progression of autoimmune diseases [19]. However, it remains unknown which CLRs affect MDSCs and involve in the progression of SLE.

This study aimed to investigate the expression of CLRs in the development of SLE. We found that symptoms of lupus were relieved in Dectin3-deficient mice via regulating the accumulation and function of MDSCs. Moreover, Dectin3 promoted the expression of LOX-1 on M-MDSCs to increase the Th17/Treg cell imbalance, indicating that LOX-1+ M-MDSCs could be regarded as new target cells for treating lupus.

MATERIALS AND METHODS

Mice

Female wild-type (WT) C57BL/6 J mice (6–8 weeks old) were brought from the Model Animal Research Center of Nanjing University (Nanjing, China). Dectin3−/− mice were generated as previously described [20] and crossed to C57BL/6 J background (96.88%) [15]. WT mice and Dectin3−/− mice were housed under pathogen-free conditions in a 12 h light and dark cycle. All procedures involving mice were based on the institutional guidelines for animal care and approved by the Animal Care Committee at Nanjing University (SCXK-Jiangsu-2019-0056). All animals were acclimatized for 2 weeks before experiments. For establishing the pristane-induced lupus mouse model, the mice were injected with pristane (500 µL) by intraperitoneal injection for the following 7 months. For generating imiquimod-induced mice with lupus, the right ears of the mice were treated with 1.25 mg of 5% imiquimod cream every other day for the following 10 weeks.

Antibody and reagents

Antibodies against phosphorylated FoxO1 (Ser256, 9641), phosphorylated Akt1 (Ser473, 9018), phosphorylated Syk (Tyr525/526, 2710), FoxO1 (3231E, 13198), Bim (2933), Bcl2 (3498), Bax (2772), PCNA (13110), and β-actin (4970) for western blot analysis were bought from Cell Signaling Technology. The antibody against LOX-1 (DF6522) for western blot analysis was obtained from Affinity. The anti-IgG antibody for immunofluorescence staining was bought from Abcam. The enzyme-linked immunosorbent assay (ELISA) kits for mouse dsDNA, total IgG, and IgM were purchased from FMS. The ELISA kits for mouse creatinine and blood urea nitrogen were obtained from Wako Pure Chemical Industries. The ELISA kit for mouse urine protein was procured from Bethyl Laboratories. The anti-CD11b-fluorescein isothiocyanate (FITC) antibody, Gr1-allophycocyanin (APC) antibody, CD4-FITC antibody, CD69-APC antibody, B220-APC antibody, CD25-APC antibody, CD45-PerCp, Ly6G-phycocerythrin (PE), Ly6C-APC, FoxP3-PE antibody, and IL-17-PE antibody for mouse detection were obtained from Biolegend. The mouse LOX-1-PE antibody for mouse urine protein was procured from Miltenyi Biotec. The puriﬁed CD3 and CD28 antibodies were obtained from eBioscience. The probe of carboxyﬂuorescein succinimidyl ester (CFSE) was brought from Thermo Fisher Scientiﬁc. The PI and Annexin-V were obtained from FMS.

Isolation of MDSCs and MDSC suppression assay

Spleen tissue- and bone marrow (BM)-derived MDSCs in mice were purified using an MDSC isolation kit. CD4+ T cells were pretreated with CFSE following the manufacturer’s protocols. The CD4+ T cells (2 × 10^5 cells/well) were co-cultured with purified MDSCs at 1:2 ratio in a 96-well round-bottom plate pretreated with 4 µg/mL anti-CD3 monoclonal antibody and 2 µg/mL anti-CD28 monoclonal antibody for 72 h. Then, the cells were collected to detect the proliferation of CD4+ T cells using flow cytometry.

In vitro generation of mouse MDSCs

The thiabane and femira were removed from 8- to 10-week-old C57BL/6 J mice, and BM cells were flushed. Then, BM cells were supplemented with Roswell Park Memorial Institute Medium (RPMI) 1640, and 40 ng/mL murine IL-6 and 40 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) were added for 4 days.

ELISA

Anti-dsDNA, IgG, IgM, BUN, creatinine, and urine proteins were measured using ELISA kits following the manufacturer’s protocols.

Quantitative reverse transcription-PCR

Total RNA was isolated using TRIzol reagent following the manufacturer’s protocols. Real-time PCR was performed using SYBR green dye on Step One sequence detection system (Applied Biosystems, MA, USA). The relative abundance of genes was calculated using the 2^−ΔΔCT method, and GAPDH or PBGD as the internal control. The primers used in the study are listed in Supplementary Table 1.

Western blot analysis

The cells were lysed with cell lysis buffer (Beyotime P0013B) supplemented with the protease inhibitor complex (Beyotime P1006). The nuclear and cytoplasmatic proteins were extracted using a nuclear and cytoplasmatic protein extraction kit (Beyotime P0027) following the manufacturer’s protocols. The protein concentrations in the extracts were detected using the BCA assay (Beyotime P00125). Equal amounts of the protein sample were loaded to polyvinylidene difluoride membranes. The membranes were blocked with 5% BSA dissolved in TBST (50 mM Tris/ HCl, pH 7.6, 150 mM NaCl, and 0.1% Tween-20) for 2 h at room temperature and incubated with the indicated primary antibody overnight at 4 °C, followed by incubation with appropriate enzyme horseradish peroxidase-labeled secondary antibody for 2 h at room temperature. Protein bands were visualized using ECL plus western blotting detection reagents (Millipore, MA, USA). The blot images were captured using the FluorChem8000 imaging system (Alpha-Innotech, CA, USA). The gray values were analyzed using ImageJ gel analysis software [21].

Histological analysis

The kidneys were fixed with 4% paraformaldehyde in phosphate buffer. Paraffin-embedded samples were sectioned at 3 µm and then stained with hematoxylin and eosin (HE) or periodic acid-Schiff (PAS).

Immunofluorescence staining

Paraffin-embedded kidney tissues were used in the study. Then, the heat-mediated antigen retrieval was used to treat the slides with citrate buffer. The slides were treated with the primary antibody against mouse IgG-FITC (Servicebio) overnight at 4 °C. The slides were counterstained with DAPI for 5 min. Fluorescence images were captured using a laser scanning confocal microscope (FV3000, Olympus Corporation, Japan).

Flow cytometry analysis

The BM, kidney, and spleen cells were used to prepare single-cell suspensions. Then, the red cells were lysed, filtered through 70-µm cell strainers, and collected by centrifugation at 300 × g for 5 min at 4 °C. After washing, the cells were immediately prepared for flow cytometry. For detecting cell surface markers, the cells were pre-incubated with the
primary antibody for 30 min at 4 °C in the dark and then washed with phosphate-buffered saline (PBS). For detecting intracellular markers (IL-17A), the cells were re-stimulated with phorbol myristate acetate (PMA; 25 ng/mL) and ionomycin (250 ng/mL) for 6 h in the presence of brefeldin A prior to the staining of cell surface markers. The Treg cells were surface labeled with CD4 and CD25 for 30 min at 4 °C in the dark, followed by fixation, permeabilization, and intracellular staining with Foxp3 for another 30 min at 4 °C in the dark. The mouse Th17 cells were surface labeled with CD4 and CD25 for 30 min at 4 °C in the dark, followed by fixation, permeabilization, and intracellular staining with Foxp3 for another 30 min at 4 °C in the dark. The mouse Th17 cells were surface labeled with CD4 and CD25 for 30 min at 4 °C in the dark, followed by fixation, permeabilization, and intracellular staining with Foxp3 for another 30 min at 4 °C in the dark. The mouse Th17 cells were surface labeled with CD4 and CD25 for 30 min at 4 °C in the dark, followed by fixation, permeabilization, and intracellular staining with Foxp3 for another 30 min at 4 °C in the dark.

| Active group | Inactive group |
|--------------|----------------|
| n = 35       | n = 24         |
| Age (year, mean ± SD) | 45 ± 8 | 41.2 ± 5.1 |
| Gender (female/male) | 30/5 | 21/3 |
| SLEDAI < 8   | 35 (94.6%) |

SLEDAI ≥ 8

| n (%) | 35 (94.6%) |

**Human samples**

A total of 59 patients with SLE who visited the Department of Rheumatology, Nanjing Drum Tower Hospital (Nanjing, China) were prospectively enrolled. All SLE patients were diagnosed according to the criteria set out by American College of Rheumatology revised criteria in 1997 [22]. Patients who had other autoimmune diseases; had a history of familial hyperlipidemia and/or thyroid disease, diabetes mellitus, and/or other rheumatic diseases; or took lipid-lowering agents or thyroid medications were excluded. The disease activity of these patients was measured using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [22]. Disease activity was evaluated using the SLEDAI and a cutoff of ≥8 was used to define active disease (Table 1). This study was approved by the ethics committee at The Affiliated Drum Tower Hospital of Nanjing University Medical School (ID: SC201700201) and undertaken according to the guidelines of the Declaration of Helsinki. At entry, patients completed a standardized medical history, laboratory tests, and analyses. All the detections were carried out at the clinical laboratory of Nanjing Drum Tower Hospital.

**Screening of differentially expressed genes**

The samples of MDSCs were analyzed by microarray hybridization in Beijing Oligo Biotech Co. (Beijing, China). The preliminary progression was analyzed after obtaining the raw data. The fold value represented the degree of differential expression between MDSCs of WT mice with lupus and Dectin3-deficient mice with lupus. The standard used to judge differential expression was as follows: the gene expression from the MDSCs of WT mice with lupus was used as a valid gene. Compared with the MDSCs of WT mice with lupus, a fold change of <1.0 indicated a downregulated gene, while a fold change of >1.0 indicated an upregulated gene. Genes with a fold change >1.5 or <0.5 compared with those in the control group were selected for further analysis [23].

**Results**

**Lupus symptoms were relieved in pristane-induced lupus in Dectin3−/− mice**

We analyzed the expression of CLR expression in SLE progression (Fig. S1), suggesting that Dectin3 was a key molecule in the development of SLE patients. To further determine the role of Dectin3 in the lupus process, the pristane-induced lupus model was constructed according to the schematic diagram (Fig. 1A). Splenomegaly reduced in Dectin3−/− lupus mice compared with that in WT lupus mice (Fig. 1B). The serum levels of anti-dsDNA, anti-total IgG, IgM, BUN, and creatinine were reduced in Dectin3−/− lupus mice compared with those in WT lupus mice (Fig. 1C–G). The level of 24 h albuminuria in Dectin3−/− lupus mice was lower than that in WT lupus mice from the fifth month (Fig. 1H). The histopathological renal assessment showed decreased infiltration of crescentic and renal interstitial inflammatory cells in Dectin3−/− mice with lupus compared with WT mice with lupus (Fig. 1I, J). The glomeruli IgG deposits decreased in Dectin3−/− mice with lupus compared with WT mice with lupus, indicating glomerulonephritis with immune complex deposits (Fig. 1K).

The activations of B and T cells of the spleen were inhibited in Dectin3-deficient mice with lupus compared with WT mice with lupus (Figs. S2–S3). All the data suggested that Dectin3 deficiency protected against the progression of the lupus-like disease.

**Adaptive transfer of MDSCs from Dectin3−/− mice with lupus relieved imiquimod-induced lupus symptoms**

To determine whether Dectin3 promotes the lupus development involved in regulating MDSC accumulation, the change in the numbers of MDSCs was detected by Flow cytometry in PBMCs,
BM, SP, and Kd in each group. The percentages and absolute numbers of MDSCs in PBMCs, BM, SP, and Kd were lower in Dectin3−/− mice with lupus than in WT mice with lupus (Fig. 2A, B). Meanwhile, the function of MDSCs was improved in Dectin3−/− mice with pristane-induced lupus (Fig. S4).

Purified MDSCs (1 × 10^6 cells/mouse) were injected into WT mice with lupus according to the schematic diagram (Fig. 2C). The splenomegaly was relieved in mice with the adoptive transfer of MDSCs (MDSC-group mice) compared with mice in the PBS group (Fig. 2D). The serum levels of anti-dsDNA, anti-total IgG, IgM, BUN, Cre, and albuminuria significantly decreased in the MDSC-group mice compared with the PBS-group mice (Fig. 2E–J). The lupus nephritis was detected by HE and PAS staining and the amount of glomeruli IgG deposits reduced in the MDSC group compared with the PBS group (Fig. 2K–M). The balance of Th17 and Treg cells improved in the MDSC group compared with the PBS group (Fig. 2N). The expansion of MDSCs in PBMC, BM, SP, and Kd significantly reduced in the MDSC group compared with the PBS group (Fig. S5A–H). In addition, the activation of B and T lymphocytes significantly reduced in the MDSC group compared
Fig. 2  Adoptive transfer of MDSCs from Dectin3−/− mice with lupus alleviated the induction of lupus-like disease. A Representative flow cytometry results of MDSCs in PBMC, BM, SP, and Kd of each group. B Statistical data of percentages and absolute counts of MDSCs in PBMC, BM, SP, and Kd. C Schematic diagram of the adoptive transfer of MDSCs. D Representative photographs of the spleen and spleen weights in the MDSC and PBS groups. E-I ELISA of the serum levels of anti-dsDNA, anti-total IgM, IgG, BUN, and Cre in the MDSC and PBS groups. J The level of 24-h mouse urine protein was measured using ELISA. K, L HE and PAS staining of kidney sections in the MDSC and PBS groups (scale bar = 10 μM). M Amounts of IgG deposits in glomeruli were measured using immunofluorescence analysis (scale bar = 30 μM). N Flow cytometry analysis detected the percentages of Th17 and Treg cells. Data represent the mean scores ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; n = 7–9 mice in each group.
with the PBS group (Fig. S3A–H). These data indicated that Dectin3−/− mice depended mainly on the regulation of MDSCs to relieve lupus progression.

**Dectin3 deficiency promoted FoxO1-mediated apoptosis and reduced the accumulation of MDSCs**

To explore the molecular mechanism underlying the reduction in MDSC accumulation, MDSCs were isolated from pristane-induced WT and Dectin3−/− mice with lupus to perform transcriptome microarray assays (Fig. 3A). According to the analysis pipeline, we analyzed the differential expression genes of MDSCs from the spleen between WT lupus mice and Dectin3−/− lupus mice, and the results were shown on a heatmap (Fig. 3A). Then, these candidates were addressed by performing a secondary screening by using the global signal-transduction network based on the significantly regulated GOs and pathways to determine the core different genes, and the top 10 genes were found to possess the score of a degree above 30 (Fig. 3B). To further narrow down the candidates, we then used a QPCR assay to screen for the ones that highly correlated with the SLE process in MDSCs isolated from the spleen and WT lupus mice and Dectin3−/− lupus mice. Among these 10 genes, FoxO1, which is involved in regulating cell apoptosis and survival, showed the most change fold in MDSCs from Dectin3−/− lupus mice compared with WT lupus mice, whereas the other candidates showed a little or moderate change (Fig. 3C). In addition, the nuclear transfer of FoxO1 increased in MDSCs of Dectin3−/− mice with lupus (Fig. 3D). The flow cytometry analysis results indicated that the percentage of MDSC apoptosis was higher in Dectin3−/− mice than that in WT lupus mice (Fig. 3E). And the protein expressions of Bim and Bax increased in MDSCs from Dectin3−/− mice compared with WT lupus mice; however, the expression of Bcl2 in MDSCs of Dectin3−/− mice with lupus was lower than that in WT mice with lupus (Fig. 3F). The apoptosis level of MDSCs in Dectin3−/− mice increased following FoxO1 interference (Fig. 3G–J).

To confirm whether Dectin3 promotes FoxO1-mediated MDSC accumulation and abnormal immunomodulatory function in vivo, FoxO1-high-expressed adenovirus (0.2 mL of 1 × 1011) and 0.2 mL of empty adenovirus were injected into WT mice with lupus intravenously (Fig. 3K, left). Meanwhile, Si-FoxO1 RNA fragment (0.2 mL of 15 nmol) and 0.2 mL of negative control fragment were injected into Dectin3−/− mice with lupus intravenously (Fig. 3K, right). The results showed that percentages of MDSCs increased in BM, spleen, and kidney of Si-FoxO1 Dectin3−/− mice with lupus compared with WT mice with lupus (Fig. 3K). The nuclear transfer of FoxO1 in Si-FoxO1 Dectin3−/− mice with lupus was lower than that in WT mice with lupus (Fig. 3K). The percentage of apoptotic MDSCs decreased in Si-FoxO1 Dectin3−/− mice with lupus compared with WT mice with lupus (Fig. 3K). These data indicated that Dectin3 deficiency promoted FoxO1-mediated apoptosis to decrease the expansion of MDSCs in lupus development in vitro and in vivo.

**Syk-Akt1-mediated nuclear transfer of FoxO1 reduced in MDSCs of Dectin3−/− mice with lupus**

To further explore the molecular mechanism of regulating the nuclear transfer of FoxO1 in Dectin3-deficient MDSCs, a co-expression network of differentially expressed genes with a hub of FoxO1 was used. FoxO1 is regulated by the PI3K/Akt1 pathway and associated with cell survival and apoptosis progression (Fig. 4A). The phosphorylation of Akt1 and Syk reduced in MDSCs of Dectin3−/− mice with lupus compared with WT mice with lupus (Fig. 4B, C). BM-MDSCs with Syk and Akt1 interference fragments were transfected for 12 and 24 h (Fig. 4D, E) and then treated with R848 for 24 h to confirm whether Dectin3 regulated the nuclear transfer of FoxO1 via the Syk-Akt1 signal. BM-MDSCs transfected with Akt1 RNA fragment significantly reduced the nuclear transfer of FoxO1 after R848 stimulation (Fig. 4F, G). The data showed that Dectin3 inhibited Syk-Akt1-mediated nuclear transfer of FoxO1.

**Interference of FoxO1 promoted the induction of lupus-like disease in Dectin3−/− mice**

To further confirm whether Dectin3 promoted lupus progression via inhibiting FoxO1 expression, FoxO1-high-expression adenovirus (0.2 mL of 1 × 1011) and 0.2 mL of empty adenovirus were injected into WT mice with lupus intravenously (Fig. 3K, left). Si-FoxO1 RNA fragment (0.2 mL of 15 nmol) and 0.2 mL of negative control fragment were injected into Dectin3−/− mice with lupus intravenously (Fig. 3K, right). The results showed that the splenomegaly in AAV-FoxO1 WT mice with lupus was significantly relieved compared with that in AAV-NC-group mice. However, the splenomegaly in Si-FoxO1 Dectin3−/− mice with lupus was higher than in Si-NC-group mice (Fig. 5A, B). The serum Anti-dsDNA and BUN were higher in Si-FoxO1 Dectin3−/− mice with lupus than in Si-NC-group mice (Fig. 5C, D). The symptoms of lupus nephritis were significantly aggravated in Si-FoxO1 Dectin3−/− mice with lupus compared with Si-NC-group mice, including decreased infiltration of crescentic and renal interstitial inflammatory cells and reduced amounts of glomeruli IgG deposits (Fig. 5E–I). These data indicated that the downregulation of FoxO1 exacerbated the progression of Dectin3−/− lupus-deficient mice.

**FoxO1 negatively regulated LOX-1 expression in M-MDSCs from Dectin3−/− mice**

Compared with WT lupus mice, the expansion of M-MDSCs significantly decreased in Dectin3−/− lupus mice was revealed (Fig. S7). To perform transcriptome microarray assays so as to explore the molecular mechanism of how Dectin3 influenced M-MDSC, M-MDSCs were isolated from pristane-induced WT mice and Dectin3−/− mice with lupus (Fig. 6A). M-MDSCs own the heterogeneity, and the differential expression of surface markers on M-MDSCs has a different role in SLE. Thus, we analyzed different genes of surface markers. The expression of OLR1 (LOX-1 protein gene) significantly decreased in M-MDSCs of Dectin3−/− lupus mice compared with WT mice with lupus (Fig. 6B, C). The data suggested that the expression of LOX-1 on M-MDSCs of SP, BM, and Kd significantly decreased in Dectin3−/− lupus mice compared with WT mice with lupus (Fig. S8).

Dectin3 deficiency promoted FoxO1-mediated nuclear transfer of LOX-1-deficient M-MDSCs. To further determine the molecular mechanism of regulating the expression of OLR1 on Dectin3-deficient M-MDSCs, the expression of FoxO1 significantly increased in M-MDSCs of Dectin3−/− mice with lupus compared with WT mice with lupus (Fig. 6D, E). The miRNA expression of FoxO1 negatively correlated with OLR1 in Dectin3-deficient M-MDSCs (Fig. 6F). When FoxO1 was further overexpressed in BM-M-MDSCs and then stimulated with R848, the protein expression of LOX-1 increased (Fig. 6G). The expression of LOX-1 on M-MDSCs increased in BM, spleen, and kidney of Si-FoxO1 Dectin3−/− mice with lupus compared with WT mice with lupus (Fig. 6H–Q). In vivo, above all, the results suggested that FoxO1 negatively regulated the expression of LOX-1 in M-MDSCs in vitro and in vivo.

**LOX-1− M-MDSCs promoted the differentiation of Th17 cells**

To explore the effect of LOX-1 expression on the immunoregulatory function of M-MDSCs, LOX-1− M-MDSCs promoted the accumulation of Th17 cells and inhibited the differentiation of Treg cells, LOX-1− M-MDSCs, and LOX-1− M-MDSCs from mice with lupus were co-cultured with CD4+ T cells from normal mice in different conditional media (Fig. 7A–C). The results showed that the inhibitory effect on the proliferation of CD4+ T cells was lower in LOX-1− M-MDSCs than in LOX-1− M-MDSCs (Fig. 7D). The data indicated that LOX-1− M-MDSCs promoted the accumulation of proinflammatory Th17 cells.
Increased Dectin3 expression had a positive correlation with the accumulation of LOX-1+ M-MDSCs in patients with SLE. Disease activity was evaluated using the SLEDAI and a cutoff of ≥8 was used to define active disease (Table 1). Flow cytometric analysis of Dectin3 and statistical analysis of relative MFI of Dectin3 on M-MDSCs of peripheral blood from SLE patients (Fig. 8A, B). The results showed that Dectin3 was overexpressed on M-MDSCs of the active SLE group compared with the inactive SLE group (Fig. 8D). Moreover, the expression FoxO1 in M-MDSCs of peripheral blood from SLE patients was detected by flow...
Cytometry (Fig. 8A, C). The downregulation of FoxO1 in M-MDSCs of the active group was detected compared with the inactive group (Fig. 8E). LOX-1 on M-MDSCs of peripheral blood from SLE patients was analyzed by flow cytometry (Fig. 8A) and the results showed that the relative expression of LOX-1 was increased on M-MDSCs of the active SLE group compared with the inactive SLE group (Fig. 8F). Furthermore, the correlation between SLEDAI scores and Dectin3, FoxO1, and LOX-1 levels in M-MDSCs was analyzed by linear regression (stepwise). The data suggested that Dectin3 and LOX-1 levels on M-MDSCs from SLE patients were positively correlated with SLEDAI scores (Fig. 8G, I), whereas the correlation between FoxO1 in M-MDSCs from SLE patients and SLEDAI score was negative (Fig. 8H). All the clinical data indicated that Dectin3 expression probably was positively correlated with LOX-1 level on M-MDSCs in SLE patients, which involved in the FoxO1 pathway.

**DISCUSSION**

Dectin3 is mainly expressed on the surface of myeloid cells and is an important type of pattern recognition receptor that can recognize sugar components on the cell wall of pathogens [24, 25]. The role of Dectin3 has been shown to promote antifungal immunity against *Candida spp.*, *Fonsecaea pedrosoi*, and *Blastomyces*...
dermatitidis infections [18]. Studies reported that Dectin2 might be related to fungal-induced autoimmune diseases [26, 27], and the formation of Dectin3/Dectin2 heterodimer complexes had a greater ability of antifungal immune response. But the role of Dectin3 in autoimmune diseases remains unknown. This study was novel in exploring the role of Dectin3 in the pathogenesis of lupus.

The lupus symptoms of Dectin3−/− mice were relieved compared with those in WT lupus mice (Figs. 1–2). But the mechanism of Dectin3 to regulate the SLE progress remains uncertain. Our previous studies suggested that MDSCs played a vital role in the pathogenesis of SLE [24–26, 28]. However, our previous study indicated Card9 (the downstream adaptor protein of Dectin3) reduced the incidence of colorectal cancer by inhibiting MDSCs recruitment [15]. Meanwhile, Card9 relieved the incidence of lung cancer by reducing IDO production in MDSCs [16]. Whether the role of Dectin3 in regulating the lupus process depends on MDSCs remains unknown.

Therefore, adoptive transfer experiments were addressed to explore whether Dectin3 regulates the lupus process via MDSCs. The data indicated that the spleens of the serum levels of dsDNA antibody, total IgG, and IgM antibody of Dectin3−/− MDSC transplantation group were significantly lower than those in the PBS group (Fig. 2C–J). In addition, the kidney damage was significantly relieved in the MDSC transplantation group compared with the PBS group (Fig. 2K–M). The data indicated that the role of Dectin3 in alleviating lupus symptoms via regulating MDSCs.

To further determine the molecular mechanism of Dectin3 in regulating MDSCs accumulation and function, we analyzed the mRNA expression profile of MDSCs in WT and Dectin3−/− lupus mice. The results of the transduction network of the differential expressed genes were analyzed by bioinformatics, combined with the GO and pathway analysis, which revealed that FoxO1 was mainly involved in pathophysiological processes such as cell proliferation, apoptosis, and oxidative stress [29–32]. Researches showed that FoxO1 mRNA expression in PBMCs of SLE patients was lower than that in healthy controls, which negatively correlated with SLEDAI. Our results indicated that Dectin3 negatively correlated with FoxO1 gene expression in MDSCs isolated from lupus mice.

The bioinformatics analysis showed that the FoxO1 signal was mainly concentrated in the biological processes of MDSC apoptosis, oxidative stress, cell proliferation, and so forth. In MDSCs of Dectin3−/− mice with lupus, the phosphorylation level

![Fig. 5](image_url)
of FoxO1 was significantly downregulated, and the level of nuclear metastasis of FoxO1 significantly increased (Fig. 3C). At the same time, the expression levels of pro-apoptotic proteins Bim and Bax in MDSCs of Dectin3−/− mice with lupus significantly increased, and the expression of anti-apoptotic protein Bcl2 significantly decreased (Fig. 3D). The aforementioned results indicated that Dectin3 regulated the number of MDSCs by regulating the nuclear transfer level of FoxO1. FoxO1 (Thr24, Ser256, and Ser319) was phosphorylated by Akt, which was transported from the nucleus to the cytoplasm, resulting in
the loss of transcriptional activity, thereby inhibiting the expression of downstream genes regulated by FoxO1. The acetylation of FoxO1 weakened the ability to bind to homologous DNA sequences while enhancing the phosphorylation of FoxO1, further reducing its transcriptional activity [29–31, 33, 34].

Dectin3 can induce Card9/Bcl-10/Malt1 to form a complex by activating Syk, which in turn activates NF-κB and other pathways, initiating the innate immune response, and mediates adaptive immune response [32, 35]. In addition, studies pointed out that the Syk gene could bind to the promoter region of Akt1 to promote its transcriptional activation, thereby promoting cell proliferation [36, 37]. Dectin3 inhibited the nuclear metastasis of FoxO1 in lupus MDSCs through the Syk-Akt1 signal axis and the development of lupus [42]. LOX-1 in the lupus environment had a stronger immunosuppressive function on T cells and promoted tumorigenesis [39–41]. Also, low-density granulocytes with high LOX-1 expression in the lupus environment inhibited the proliferation of T cells to a lesser extent compared with LOX-1 expression in mice with lupus mice.

Recent studies showed that a large number of accumulated M-MDSCs were involved in the development of lupus [38]. The exact mechanism of the increase in the number of MDSCs in patients and mice with lupus is still unclear. This may be related to the lack of specific surface markers of MDSCs, which, to some extent, hinders the understanding of the complex regulatory process of MDSCs. The magnetic bead sorting method was used to sort and purify the M-MDSCs in the spleen of WT mice and Dectin3-/- mice with lupus followed by gene chip analysis.

Studies confirmed that G-MDSCs with the high expression of LOX-1 in the tumor environment had a stronger immunosuppressive function on T cells and promoted tumorigenesis [39–41]. Also, low-density granulocytes with high LOX-1 expression in the lupus environment had no significant immunosuppressive ability on T cells, but promoted the production of inflammatory T cells and the development of lupus [42]. LOX-1-/- M-MDSCs in the lupus environment inhibited the proliferation of T cells to a lesser extent compared with LOX-1-/- M-MDSCs and promoted Th17/Treg imbalance.

The M-MDSCs in the spleens of different groups of mice with lupus were further sorted and enriched, revealing that the apoptosis level of M-MDSCs after knocking down FoxO1 significantly decreased, and the increase in the number of inflammatory Th17 cells was promoted in Dectin3-/- lupus mice. These data indicated that LOX-1-/- M-MDSCs were related to the exacerbation of the lupus process and might be potential target cells for lupus.
Fig. 8 Dectin3 expression positively correlated with the level of LOX-1 on M-MDSCs in patients with SLE. A Schematic diagram of flow cytometric detection of peripheral blood MDSCs and M-MDSCs in patients with SLE, and LOX-1 expression detection diagram in M-MDSCs (10 samples in the inactive stage of the disease and 10 samples in the active stage of the disease). B, C Flow cytometry analysis of Dectin3 (up) and FoxO1 (down) expression in peripheral blood MDSCs. D–F Statistical data of the expression of Dectin3, FoxO1, and LOX-1 in peripheral blood MDSCs. G–I The correlations of Dectin3, FoxO1, and LOX-1 expressions with the score of SLEDAI. J Schematic diagram of the regulation of the accumulation in Dectin3-deficient mice with lupus. Data represent the mean scores ± SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001; active group: n = 35, inactive group: n = 24.
DATA AND MATERIALS AVAILABILITY
All data generated or analyzed during the study are included in the article.

REFERENCES
1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.
2. Salazar-Aldrete C, Galán-Díez M, Fernández-Ruiz E, Niño-Moreno P, Estrada-Capetillo L, Abd-Mendoza C, et al. Expression and function of dectin-1 is defective in monocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol. 2013;33:368–77.
3. Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. Associations between TLR polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Rheumatol. 2012;30:262–5.
4. Fagnoni P, Manganò K, Mammana S, Quattrocorci C, Magro G, Coco M, et al. Acceleration of SLE-like syndrome development in NZBxNZW F1 mice by beta-glucan. Lupus. 2014;23:407–11.

Monrad SU, Rea K, Thacker S, Kaplan MJ. Myeloid dendritic cells display down-regulation of C-type lectin receptor expression and aberrant lectin uptake in systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R114.

Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7:718–29.

Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288:136–48.

Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7:718–29.

Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288:136–48.

Gorakiewicz DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.

Veglia F, Peregno M, Gabriovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2019;20:108–19.

Pang B, Zhen Y, Hu C, Ma Z, Lin S, Yi H. Myeloid-derived suppressor cells shift Th17/Treg ratio and promote systemic lupus erythematosus progression through arginase-1/mir-322-5p/TGFβ pathway. Clin Sci (Lond). 2020;134:2209–22.

Wu H, Zhen Y, Ma Z, Li H, Yu J, Xu ZG, et al. Arginase-1-dependent promotion of Th17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med. 2016;8(331):331ra340.

Ji J, Xu J, Zhao S, Liu F, Qi J, Song Y, et al. Myeloid-derived suppressor cells contribute to systemic lupus erythematosus by regulating differentiation of Th17 cells and Tregs. Clin Sci (Lond). 2016;130:1453–67.

Zhang D, Xu J, Ren J, Ding L, Shi G, Li D, et al. Myeloid-derived suppressor cells induce podocyte injury through increasing reactive oxygen species in lupus nephritis. Front Immunol. 2018;9:1443.

Shi G, Li D, Li X, Ren J, Xu J, Ding L, et al. mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b+Gr1+ cells. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1–13.

Wang T, Fan C, Yao A, Xu X, Zheng G, You Y, et al. The adaptor protein CARD9 protects against colon cancer by restricting mycobacteria-mediated expansion of myeloid-derived suppressor cells. Immunity. 2018;49:504–14. e504.

Qu J, Liu L, Xu R, Qian J, Xu Z, Dou H, et al. CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production. Int J Cancer. 2019;145:2225–37.

Rieber N, Singh A, Oz H, Carevic M, Bouzamani M, Amich J, et al. Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. Cell Host Microbe. 2015;17:507–14.

Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, et al. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol. 2013;43:1220–30.

Del Fresno C, Iborra S, Saz-Leal P, Martínez-López M, Sancho D. Flexible signaling of myeloid C-type lectin receptors in immunity and inflammation. Front Immunol. 2018;9:904.

Zhu LL, Zhao XQ, Jiang C, You Y, Chen XP, Jiang YY, et al. C-type lectin receptor dectin-3 and dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity. 2013;39:324–34.

Li D, Qi J, Wang J, Pan Y, Li J, Xia X, et al. Protective effect of dihydroartemisinin in inhibiting senescence of myeloid-derived suppressor cells from lupus mice via Nrf2/HO-1 pathway. Free Radic Biol Med. 2019;143:260–74.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1990;40:1725.

Li D, Wang H, Fang J, Zhai J, Wang R, Shen X, et al. Microarray gene expression analysis of chemosensitivity for doxetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma. Chin J Cancer Res. 2017;29:204–12.

Huang HR, Li F, Han H, Xu X, Li N, Wang S, et al. Dectin-3 recognizes glucuronoxyllanomann of cryptococcus neoformans serotype AD and cryptococcus gatti serotype B to initiate host defense against cryptococcosis. Front Immunol. 2018;9:1781.
ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04052-5.

Correspondence and requests for materials should be addressed to Tingting Wang, Jun Liang, Huan Dou or Yayi Hou.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.